Insider Analysis From Sidley Austin LLP: Getting Ready For China’s Anti-Monopoly Law
This article was originally published in PharmAsia News
Executive Summary
By Chen Yang, Sidley Austin Beijing; and Adrian Emch, Sidley Austin Brussels
You may also be interested in...
Nestle To Become No. 1 In China's Infant Formula Market Following Pfizer Nutrition Acquisition
With roughly 60% of Pfizer Nutrition sales coming from Asia, and 47% of that from China, Nestle slips into No. 1 spot in China’s infant formula market.
Nestle To Become No. 1 In China's Infant Formula Market Following Pfizer Nutrition Acquisition
With roughly 60% of Pfizer Nutrition sales coming from Asia, and 47% of that from China, Nestle slips into No. 1 spot in China’s infant formula market.
China's MOFCOM Promises Increased Scrutiny Over M&A In 2012
China Ministry of Commerce announcement of increased M&A scrutiny, sends companies scrambling to submit papers in fear of bureaucratic delays.